ZNTL vs. PRLD, CYRX, IGMS, IRWD, IRON, CGEM, COLL, BCYC, ANAB, and CRON
Should you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Prelude Therapeutics (PRLD), Cryoport (CYRX), IGM Biosciences (IGMS), Ironwood Pharmaceuticals (IRWD), Disc Medicine (IRON), Cullinan Therapeutics (CGEM), Collegium Pharmaceutical (COLL), Bicycle Therapeutics (BCYC), AnaptysBio (ANAB), and Cronos Group (CRON).
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends.
79.7% of Prelude Therapeutics shares are held by institutional investors. 6.1% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 62.8% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Prelude Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Zentalis Pharmaceuticals presently has a consensus target price of $11.33, suggesting a potential upside of 153.54%. Prelude Therapeutics has a consensus target price of $4.75, suggesting a potential downside of 17.96%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Prelude Therapeutics.
Zentalis Pharmaceuticals received 30 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 62.50% of users gave Zentalis Pharmaceuticals an outperform vote while only 47.17% of users gave Prelude Therapeutics an outperform vote.
Zentalis Pharmaceuticals' return on equity of -46.05% beat Prelude Therapeutics' return on equity.
Zentalis Pharmaceuticals has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.
In the previous week, Zentalis Pharmaceuticals had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 2 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.89 beat Zentalis Pharmaceuticals' score of 0.37 indicating that Prelude Therapeutics is being referred to more favorably in the news media.
Summary
Zentalis Pharmaceuticals beats Prelude Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Zentalis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zentalis Pharmaceuticals Competitors List
Related Companies and Tools
